Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
D'Agostino M, Bertuglia G, Rota-Scalabrini D, Belotti A, Morè S, Corradini P, Oliva S, Ledda A, Grasso M, Pavone V, Ronconi S, Vincelli ID, Ballanti S, Velluti C, Cellini C, Gozzetti A, Palmas AD, Gamberi B, Mancuso K, Paris L, Zambello R, Petrucci MT, Bruno B, Musto P, Gay F. D'Agostino M, et al. Among authors: ronconi s. Blood. 2024 Feb 15;143(7):592-596. doi: 10.1182/blood.2023022080. Blood. 2024. PMID: 38048557
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Cavo M, et al. Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12. Blood. 2012. PMID: 22498745 Free article. Clinical Trial.
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis.
Bonello F, Pulini S, Ballanti S, Gentile M, Spada S, Annibali O, Omedé P, Ronconi S, Cangialosi C, Podda L, Palmas A, Malfitano A, Rivoli G, Belotti A, Ciambelli F, Vincelli ID, Cafro AM, Innao V, Palumbo A, Sonneveld P, Spencer A, Hájek R, Boccadoro M, Gay F. Bonello F, et al. Among authors: ronconi s. Cancers (Basel). 2019 Nov 5;11(11):1735. doi: 10.3390/cancers11111735. Cancers (Basel). 2019. PMID: 31694338 Free PMC article.
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.
Mina R, Belotti A, Petrucci MT, Zambello R, Capra A, Di Lullo G, Ronconi S, Pescosta N, Grasso M, Monaco F, Cellini C, Gobbi M, Ballanti S, de Fabritiis P, Mosca-Siez ML, Marchetti M, Liberati AM, Offidani M, Giuliani N, Ria R, Musto P, Romano A, Sonneveld P, Boccadoro M, Larocca A. Mina R, et al. Among authors: ronconi s. Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1. Blood Cancer J. 2020. PMID: 32424154 Free PMC article. Clinical Trial. No abstract available.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, Aquino S, de Fabritiis P, Giuliani N, De Rosa L, Gozzetti A, Cellini C, Bertamini L, Capra A, Oddolo D, Vincelli ID, Ronconi S, Pavone V, Pescosta N, Cea M, Fioritoni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Boccadoro M, Gay F. Mina R, et al. Among authors: ronconi s. Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14. Lancet Oncol. 2023. PMID: 36528035 Clinical Trial.
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Zannetti BA, Tacchetti P, Pantani L, Gamberi B, Tosi P, Rocchi S, Cellini C, Ronconi S, Pezzi A, Mancuso K, Rizzello I, Caratozzolo I, Martello M, Dozza L, Cavo M, Zamagni E. Zannetti BA, et al. Among authors: ronconi s. Ann Hematol. 2017 Dec;96(12):2071-2078. doi: 10.1007/s00277-017-3140-5. Epub 2017 Oct 24. Ann Hematol. 2017. PMID: 29063955 Clinical Trial.
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti P, Pantani L, Patriarca F, Petrucci MT, Zamagni E, Dozza L, Galli M, Di Raimondo F, Crippa C, Boccadoro M, Barbato S, Tosi P, Narni F, Montefusco V, Testoni N, Spadano A, Terragna C, Pescosta N, Marzocchi G, Cellini C, Galieni P, Ronconi S, Gobbi M, Catalano L, Lazzaro A, De Sabbata G, Cangialosi C, Ciambelli F, Musto P, Elice F, Cavo M; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto Italian Myeloma Network). Tacchetti P, et al. Among authors: ronconi s. Lancet Haematol. 2020 Dec;7(12):e861-e873. doi: 10.1016/S2352-3026(20)30323-9. Lancet Haematol. 2020. PMID: 33242443 Clinical Trial.
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.
Martino M, Canale FA, Alati C, Vincelli ID, Moscato T, Porto G, Loteta B, Naso V, Mazza M, Nicolini F, Ghelli Luserna di Rorà A, Simonetti G, Ronconi S, Ceccolini M, Musuraca G, Martinelli G, Cerchione C. Martino M, et al. Among authors: ronconi s. Cancers (Basel). 2021 May 27;13(11):2639. doi: 10.3390/cancers13112639. Cancers (Basel). 2021. PMID: 34072068 Free PMC article. Review.
54 results